Pharmacogenetics of the cytochrome P450 enzyme system: Review of current knowledge and clinical significance

Journal of Pharmacy Practice

Volumn 20, Issue 3, 2007, Pages 206-218

  Amal Al Omari, ^a   Murry, Daryl J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Cytochrome P450; Drug metabolizing enzymes; Genetic polymorphism; Pharmacogenetics; Poor metabolizer

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIMALARIAL AGENT; CERIVASTATIN; CITALOPRAM; CLOZAPINE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DIAZEPAM; DOCETAXEL; EFAVIRENZ; FLUVOXAMINE; IFOSFAMIDE; IMIPRAMINE; LANSOPRAZOLE; MEPHENYTOIN; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; OMEPRAZOLE; PACLITAXEL; PAROXETINE; PHENYTOIN; PROTON PUMP INHIBITOR; RETINOIC ACID; SERTRALINE; THEOPHYLLINE; UNINDEXED DRUG; WARFARIN;

CANCER RISK; CYTOTOXICITY; DRUG CLEARANCE; DRUG METABOLISM; DRUG TRANSFORMATION; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; ENZYME METABOLISM; GENE DUPLICATION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HELICOBACTER INFECTION; HUMAN; HYPERCHOLESTEROLEMIA; NONHUMAN; PHARMACOGENOMICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 38149078186     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190007304821     Document Type: Review

References (83)

1. Fishbain DA, Fishbain D., Lewis J., et al. Genetic testing for enzymes of drug metabolism: does it have clinical utility for pain medicines at the present time? A structured review. Pain Med. 2004 ; 5: 81-93.
2. Frye RF Pharmacogenetics of oxidative drug metabolism and its clinical applications. In: Pharmacogenomics. Applications to Patient Care. ACCP ; 2004: 273-307.
3. Evans WE, Relling MV Pharmacogenomics: Translating functional genomics into rational therapeutics. Science. 1999 ; 286: 487-491.
4. Oscarson M. Pharmacogenetics of drug metabolizing enzymes: importance for personalised medicine. Clin Chem Lab Med. 2003 ; 41: 573-580.
5. Rogers JF, Nafziger AN, Bertino JS Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med. 2002 ; 113: 746-750.
6. David SP Pharmacogenetics. Prim Care Clin Office Pract. 2004 ; 31: 543-559.
7. Ingelman-Sundburg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, the present and future. Trends Pharmacol Sci. 2004 ; 25: 193-200.
8. Markey SP Pathways of drug metabolism. In: Atkinson AJ Jr, Daniels CE, Dedrick RL, Grudzinskas CV, Markey SP, eds. Principles of Clinical Pharmacology. San Diego, CA: Academic Press ; 2001: 123-142.
9. Ingelman-Sundburg M., Oscarson M., McLellan RA Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci. 1999 ; 20: 342-349.
10. Nelson DR, Koymans L., Kamataki T., et al. P450 super family: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 1996 ; 6: 1-42.
11. Rodriguez-Antona C., Ingelman-Sundburg M. Cytochrome P450 and cancer. Oncogene. 2006 ; 25: 1679-1691.
12. Nebert DW, Russel DW Clinical importance of the cytochrome P450. Lancet. 2002 ; 360: 1155-1162.
13. Daly AK Pharmacogenetics of the cytochrome P450. Curr Topics Med Chem. 2004 ; 4: 1733-1744.
14. Cytochrome P450 Drug Interaction Table, at the Indiana University School of Medicine Web site. Available at: http://www.medicine.iupui.edu/flockhart/. Accessed October 4, 2006.
15. Ingelman-Sundburg M., Daly AK, Nerbert D., Oscarson M. Human Cytochrome P450 (CYP) Allele Nomenclature Committee. Available at: http://www.imm.ki.se/ CYPalleles. Accessed October 4, 2006.
16. Bartsch H., Nair U., Risch A., Rojas M., Wikman H., Alexandrov K. Genetic polymorphisms of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev. 2000 ; 9: 3-28.
17. Kawajiri K., Nakachi K., Imai K., Yoshii A., Shinoda N., Watanabe J. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Lett. 1990 ; 263: 131-133.
18. Song N., Tan W., Xing DY, Lin DX CYP 1A1 polymorphism and risk of lung cancer in relation to tobacco smoking: a case-control study in China. Carcinogenesis. 2001 ; 22: 11-16.
19. Larsen JE, Colosimo ML, Yang IA, Bowman R., Zimmerman PV, Fong KM CYP1A1 Ile462Val and MPO G-463A interact to increase risk of adenocarcinoma but not squamous cell carcinoma of the lung. Carcinogenesis. 2006 ; 27: 525-532.
20. Daly AK Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol. 2003 ; 17: 27-41.
21. Musana AK, Wilke RA Gene based drug prescribing: Clinical implications of the cytochrome P450 genes. Wisconsin Medical J. 2005 ; 104: 61-66.
22. Zevin S., Benowitz NL Drug interactions with tobacco smoking. An update. Clin Pharmacokinet. 1999 ; 36: 425-438.
23. Sachse C., Bhambra U., Smith G., et al. Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol. 2003 ; 55: 68-76.
24. Tanaka Y., Sasaki M., Kaneuchi M., Shiina H., Igawa M., Dahiya R. Polymorphisms of the CYP1B1 gene have higher risk for prostate cancer. Biochem Biophys Res Commun. 2002 ; 296: 820-826.
25. Sasaki M., Kaneuchi M., Fujimoto S., Tanaka Y., Dahiya R. CYP1B1 gene in endometrial cancer. Molecul Cellul Endocrinol. 2003 ; 202: 171-176.
26. McFadyen MC, McLeod HL, Jackson FC, Melvin WT, Doehmer J., Murry GI Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem Pharmacol. 2001 ; 62: 207-212.
27. Xu C., Goodz S., Sellers EM, Tyndale RF CYP2A6 genetic variation and potential consequences. Adv Drug Deliv Rev. 2002 ; 54: 1245-1256.
28. Rao YS, Hoffman E., Zia M., et al. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol Pharmacol. 2000 ; 58: 747-755.
29. Ariyoshi N., Miyamoto M., Umetsu Y., et al. Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. Cancer Epidemiol Biomarkers Prev. 2002 ; 11: 890-894.
30. Daigo S., Takahashi Y., Fujieda M., et al. A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics. 2002 ; 12: 299-306.
31. Gervot L., Rochat B., Gautier JC, et al. Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics. 1999 ; 9: 295-306.
32. Ekins S., Wrighton SA The role of CYP2B6 in human xenobiotic metabolism. Drug Metab Rev. 1999 ; 31: 719-754.
33. Lang t, Klein k, Fischer J., et al. Extensive genetic polymorphism in human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics. 2001 ; 11: 399-415.
34. Wang J., Sonnerborg A., Rane A., et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics. 2006 ; 16: 191-198.
35. Totah RA, Rettie AE Cytochrome P450 2C8: Substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther. 2005 ; 77: 341-352.
36. Yasar U., Lundgren S., Eliasson E., et al. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun. 2002 ; 299: 25-28.
37. Yasar U., Bennet AM, Eliasson E., et al. Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics. 2003 ; 13: 715-720.
38. Bahadur N., Leathart JB, Mutch E., et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol. 2002 ; 64: 1579-1589.
39. Ishikawa C., Ozaki H., Nakajima T., et al. A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin. J Hum Genet. 2004 ; 49: 582-585.
40. Rettie AE, Jones JP Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol. 2005 ; 45: 477-494.
41. Kirchheiner J., Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther. 2005 ; 77: 1-16.
42. Allabi AC, Gala JL, Horsmans Y., et al. Functional impact of CYP2C9*5, CYP2C9*6, CYP2C9*8, and CYP2C9*11 in vivo among black Africans. Clin Pharmacol Ther. 2004 ; 76: 113-118.
43. Lee CR, Goldstein JA, Pieper JA Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics. 2002 ; 12: 251-263.
44. Wilkinson GR Drug metabolism and variability among patients in drug response. N Engl J Med. 2005 ; 352: 2211-2221.
45. Ma MK, Woo MH, McLeod HL Genetic basis of drug metabolism. Am J Health-Syst Pharm. 2002 ; 59: 2061-2069.
46. Desta Z., Zhao X., Shin JG, Flockhart DA Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002 ; 41: 913-958.
47. Obach RS, Zhang QY, Dunbar D., Kaminsky LS Metabolic characterization of the major human small intestinal cytochrome p450s. Drug Metab Dispos. 2001 ; 29: 347-352.
48. Wedlund PJ The CYP2C19 enzyme polymorphism. Pharmacology. 2000 ; 61: 174-183.
49. Sim SC, Risinger C., Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006 ; 79: 103-113.
50. Bertilsson L., Henthorn TK, Sanz E., Tybring G., Sawe J., Villen T. Importance of genetic factors in regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther. 1989 ; 45: 348-355.
51. Kimura S., Umeno M., Skoda RC, Meyer UA, Gonzalez FJ The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet. 1989 ; 45: 889-904.
52. Griese EU, Zanger UM, Brudermanns U., et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics. 1998 ; 8: 15-26.
53. Sachse C., Brockmoller J., Bauer S., Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997 ; 60: 284-295.
54. Bertilsson L., Dahl ML, Dalén P., Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol. 2002 ; 53: 111-122.
55. Gaedigk A., Bhathena A., Ndjountche L., et al. Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans. Pharmacogenomics J. 2005 ; 5: 173-182.
56. Bertilsson L., Lou YQ, Du YL, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin. Clin Pharmacol Ther. 1992 ; 51: 388-397.
57. Masimirembwa C., Persson I., Bertilsson L., Hasler J., Ingelman-Sundberg M. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol. 1996 ; 42: 713-719.
58. Ingelman-Sundburg M., Rodriguez-Antona C. Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Phil Trans R Soc B. 2005 ; 360: 1563-1570.
59. Wuttke H., Rau T., Heide R., et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther. 2002 ; 72: 429-437.
60. Kaiser R., Sezer O., Papies A., et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotype. J Clin Oncol. 2002 ; 20: 2805-2811.
61. Hu Y., Oscarson M., Johansson I., et al. Genetic polymorphism of human CYP2E1: characterization of two variant alleles. Mol Pharmacol. 1997 ; 51: 370-376.
62. Tanaka E., Terada M., Misawa S. Cytochrome P450 2E1: its clinical and toxicological role. J Clin Pharm Ther. 2000 ; 25: 165-175.
63. Patten CJ, Thomas PE, Guy RL, et al. Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. Chem Res Toxicol. 1993 ; 6: 511-518.
64. McCarver DG, Byun R., Hines RN, Hichme M., Wegenek W. A genetic polymorphism in the regulatory sequences of human CYP2E1: association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake. Toxicol Appl Pharmacol. 1998 ; 152: 276-281.
65. Hayashi S., Watanabe J., Kawajiri K. Genetic polymorphism in the 5'-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem. 1991 ; 110: 559-565.
66. Kato S., Shields PG, Caporaso NE, et al. Cytochrome P450IIE1 genetic polymorphisms, racial variation and lung cancer risk. Cancer Res. 1992 ; 52: 6712-6715.
67. Kim RB, O'Shea D. Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin Pharmacol Ther. 1995 ; 57: 645-655.
68. Thummel KE, Wilkinson GR In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol. 1998 ; 38: 389-430.
69. Cauffiez C., Lo-Guidice JM, Chevalier D., et al. First report of a genetic polymorphism of the cytochrome P450 3A43 (CYP3A43) gene: identification of a loss of function variant. Hum Mutat. 2004 ; 23: 101.
70. Daly AK Significance of the minor cytochrome P450 3A iso-forms. Clin Pharmacokinet. 2006 ; 45: 13-31.
71. Kuehl P., Zhang J., Lin Y., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001 ; 27: 383-391.
72. Westlind-Johnsson A., Malmebo S., Johansson A., et al. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos. 2003 ; 31: 755-761.
73. Ozdemir V., Kalowa W., Tang BK, et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics. 2000 ; 10: 373-388.
74. Lamba JK, Lin YS, Schuetz EG, Thummel KE Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002 ; 54: 1271-1294.
75. Ball SE, Scatina J., Kao J., et al. Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4. Clin Pharmacol Ther. 1999 ; 66: 288-294.
76. Ando Y., Tateishi T., Sekido Y., et al. Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst. 1999 ; 91: 1587-1590.
77. Hustert E., Haberl M., Burk O., et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics. 2001 ; 11: 773-779.
78. Chou FC, Tzeng SJ, Huang JD Genetic polymorphism of cytochrome P450 3A5 in Chinese. Drug Metab Dispos. 2001 ; 29: 1205-1209.
79. Givens RC, Lin YS, Dowling AL, et al. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol. 2003 ; 95: 1297-1300.
80. Burk O., Tegude H., Koch I., et al. Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J Biol Chem. 2002 ; 277: 24280-24288.
81. Zhang J., Kuehl P., Green ED, et al. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics. 2001 ; 11: 555-572.
82. Gardiner SJ, Begg EJ Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice? Pharmacogenet Genomics. 2005 ; 15: 365-369.
83. Food and Drug Administration. Medical devices: clinical chemistry and clinical toxicology devices; drug metabolizing enzyme genotyping system. Fed Regist. 2005 ; 70: 11865-11867.